Kornimate/medical-research-clean huggingface dataset:
neoadjuvant treatment real-world clinical outcomes in nsclc

Conditions: Non-Small Cell Lung Cancer

Summary: despite the clinical success of immune checkpoint blockade (icb), in neoadjuvant setting, there is still a lack of valid data for operable nsclc in the real world. this study aim to compare the clinical outcomes (pathologic response rate versus survival) of neoadjuvant immunochemotherapy with neoadjuvant chemotherapy in the real world, to explore the impact of clinicopathological factors on clinical outcomes in neoadjuvant immunochemotherapy setting, and to identify potential neoadjuvant immunochemotherapy beneficiaries.

although the application of neoadjuvant immunotherapy in nsclc has brought a new treatment option to many patients, most evidence is based on interventional clinical trials, in which the participants are highly selected and the therapeutic strategies are restricted, resulting in limited representation. there is still a lack of large-scale multicenter real-world data to further verify the benefits in long term overall survival, identify the potential beneficiaries and optimize the therapeutic strategies of neoadjuvant immunochemotherapy. to meet the forementioned need, the investigators will perform a multi-center retrospective cohort to describe the patterns of neoadjuvant immunochemotherapy use in real world, compare the efficacy of neoadjuvant immunochemotherapy ,and evaluate prognosis of neoadjuvant immunochemotherapy.

Eligibility criteria:
inclusion criteria: 1. cytological or histological diagnosis of non-small cell lung cancer 2. patients who have previously undergone neoadjuvant immune checkpoint inhibitors and/or chemotherapy and then undergone radical surgery; 3. stage i-iii non-small cell lung cancer (iaslc/uicc staging eighth edition); 4. no previous history of malignant tumors and other malignant tumors at the same time, without any anti-tumor treatment; 5. ecog score 0-1, heart, lung, liver, brain and kidney function can tolerate surgery; 6. at least one measurable lesion (recist v1.1); 7. age \>= 18 years old and \<= 85 years old; 8. be able to abide by the visits and related procedures stipulated in the program. exclusion criteria: 1. patients included in anti-tumor drug intervention or unblinded clinical trials, in which the treatment being administered is unknown. 2. prior surgery, radiotherapy or systemic therapy for nsclc, including radiofrequency ablation, etc.

Keywords: nsclc neoadjuvant immunochemotherapy neoadjuvant chemotherapy real world study
cerebrospinal fluid collection and repository storage

Conditions: Nervous System Diseases

Summary: background: - cerebrospinal fluid (csf) is the liquid around the brain and spinal cord. many diseases can only be diagnosed by examining the csf. a lumbar puncture is used to collect and test csf. once someone is already having a lumbar puncture, a small extra amount of csf can be collected at the same time. this fluid can be used to study brain, nerve, and related health issues. researchers want to collect csf and blood samples from people who are scheduled to have a lumbar puncture. objectives: - to collect cerebrospinal fluid and blood samples from individuals who are having a lumbar puncture. eligibility: - individuals between 2 and 100 years of age who are scheduled to have a lumbar puncture for clinical or research purposes. design: * participants will have a lumbar puncture for clinical or research purposes. * during the procedure, an additional sample of csf will be collected. they will also provide a blood sample, if one is not taken at the time of the procedure. * treatment will not be provided as part of this study.

in this study we are planning to establish a repository of cerebrospinal fluid (csf), serum, and plasma. we are planning to collect a small amount of additional csf and blood on subjects who are already going to have a lumbar puncture as part of their research or clinical care at the national institutes of health (nih). this will allow us to study whether there is an association between neurological diseases and biomarkers, help identify novel pathogens infecting the central nervous system, and better enable us to understand the immune response to infections under future protocols. csf and blood as well as clinical data associated with the samples will be stored securely.

Eligibility criteria:
* subject inclusion criteria: * subjects (patients and healthy volunteers) 2 years of age and older identified to undergo lp for research or for clinical care purposes at the nih clinical center. subject exclusion criteria: -subjects (patients and healthy volunteers) with the inability to provide informed consent either directly or via a legally authorized representative. inclusion of vulnerable subjects - research involving adults who are or may be unable to consent: -the risks to all subjects involved in this research project are no more than minimal risk as we are only collecting additional csf and plasma during a lp procedure that is already being performed under a separate research protocol or as a clinically indicated procedure. at the time of the lp it will already be determined if the subject is able to give informed consent and if not a legally authorized representative will have been appointed who will decide if the additional csf and plasma can be obtained from the individual.

Keywords: biomarkers immune responses lumbar puncture neurological diseases novel pathogens natural history
radiation therapy plus amifostine in treating patients with primary prostate cancer

Conditions: Prostate Cancer; Radiation Toxicity

Summary: rationale: radiation therapy uses high-energy x-rays to damage tumor cells. amifostine may protect normal cells from the side effects of radiation therapy. purpose: phase ii trial to study the effectiveness of radiation therapy plus amifostine in treating patients with primary prostate cancer.

objectives: i. determine the incidence, grade, and time course of acute grade 2 or higher gastrointestinal and genitourinary toxicities in patients with primary prostate adenocarcinoma receiving amifostine plus fractionated radiotherapy. ii. determine the incidence and nature of toxicity associated with amifostine in these patients. iii. assess tumor response to this treatment in these patients. iv. assess impotency rates following radiotherapy in these patients. outline: this is an open label study. patients receive fractionated radiotherapy five days per week for 7 weeks plus amifostine iv push over 5 minutes, 15 minutes before each radiation treatment. patients are followed at 1 month after radiotherapy, and then every 3 months for at least 5 years. projected accrual: there will be 25 patients accrued into this study over 2 years.

Eligibility criteria:
disease characteristics: histologically confirmed prostate adenocarcinoma stage t1a-t3b n0 m0 disease psa at least 10 ng/ml prior to treatment must have a risk of seminal vesicle involvement between 10-25% no palpable or radiographic evidence of seminal vesicle involvement patient characteristics: age: 18 and over performance status: karnofsky 60-100% life expectancy: greater than 24 months hematopoietic: not specified hepatic: sgot and sgot no greater than 2.5 times upper limit of normal renal: creatinine no greater than 2.0 mg/dl cardiovascular: no severe cerebrovascular disease or sustained hypotension not secondary to antihypotensive medication other: no history of inflammatory bowel disease no history of malignancy other than nonmelanoma skin cancer no underlying medical or psychiatric illness that may impair ability to participate in study prior concurrent therapy: biologic therapy: not specified chemotherapy: not specified endocrine therapy: not specified radiotherapy: no prior radiotherapy to the prostate area surgery: no prior radical prostatectomy other: no hypertensive medications if blood pressure less than 120/70

Keywords: adenocarcinoma of the prostate stage i prostate cancer stage ii prostate cancer stage iii prostate cancer radiation toxicity
clinical-genetic investigations in children with early infantile epilepsies

Conditions: Epilepsy; Seizures, Infantile

Summary: the project strives to discover novel genetic defects that cause monogenic epilepsy or that genetically modify a preexisting epileptic phenotype. our main aim is to find genetic causes for the idiopathic west syndrome (infantile seizures) that are not caused by known cerebral malformation, lissencephaly or metabolic disorders and which have a comparatively benign prognosis. the investigators hypothesize that mutations in genes coding for ion channels or genes that modify the action of ion channels might be causative. for that the investigators will perform a sequence analysis of the coding exons of a large set of genes in all recruited patients and verify found mutations in their parents.


Eligibility criteria:
inclusion criteria: * hypsarrhythmia in the first year of life * infantile seizures in the first year of life * freedom of seizures at the age of 5 years exclusion criteria: * brain malformation * metabolic disorder * intracranial hemorrhage * lissencephaly
the ability of the change in positional perfusion index in predicting post-spinal anesthesia hypotension in caesarian section

Conditions: Obstetric Anesthesia Problems

Summary: our study aims to investigate the value of postural perfusion index changes as a non-invasive method to predict hypotension following spinal anesthesia for elective cesarean delivery.

the perfusion index is the ratio of pulsatile blood flow to non-pulsatile in peripheral tissues and can be measured non-invasively using a pulse oximeter .perfusion index measurement is considered a non-invasive rapid indicator of microcirculation variation and can help to detect circulation disturbance.it also can assess peripheral perfusion dynamics resulting from changes in peripheral vascular tone. perfusion index changes according to posture with its highest value in trendelenburg position and lowest value during 45-degree sitting position. however, to the best of our knowledge, no studies have studied the effect of posture on perfusion index in a full-term pregnancy, and its ability to predict hypotension following spinal anesthesia for elective cesarean delivery. a previous study had found a correlation between baseline perfusion index and the incidence of post-spinal hypotension in the cesarean section, however, they haven't studied the effect of postural change on pi and its predictability of post-spinal induced hypotension(,our study aims to investigate the value of postural perfusion index changes as a non-invasive method to predict hypotension following spinal anesthesia for elective cesarean delivery.

Eligibility criteria:
inclusion criteria: * asa physical status 1-2 age \> 18 years uncomplicated singleton pregnancy at full-term elective scheduled caesarian section under spinal anesthesia exclusion criteria: * pre-existing hypertension gestational hypertension or preeclampsia diabetes mellitus, or autonomic neuropathy patients with peripheral vascular diseases known fetal abnormality. emergency caesarian section. placenta previa or placenta accrete. absolute contraindications or failure to perform spinal anesthesia.study
use of mgso4 for pain after bariatric surgery

Conditions: Therapeutic Opioid Induced Constipation (Disorder)

Summary: the purpose of this study was to investigate the effect of magnesium sulfate on pain management for pain after sleeve gastrectomy operation

the purpose of this study is to investigate the effect of magnesium sulfate on pain management for pain after sleeve gastrectomy operation. design: a prospective, randomized, controlled clinical study. setting: university hospital. participants: eighty patients undergoing sleeve gastrectomy. measurements and main results: visual analog scale for pain score, sedation score, mean arterial pressure, heart rate, and valid and invalid analgesic demand will record. serum magnesium levels will determined at preoperative evaluation, postanesthesia care unit admission and at 24 hours. side effects will also record.

Eligibility criteria:
inclusion criteria: * 18 to 65 year old individuals who underwent laparoscopic sleeve gastrectomy. exclusion criteria: * one or more of the following: cardio - vascular and respiratory diseases, drug and/or alcohol abuse, use of daily an algesia 24 hours before the surgery, renal failure, and liver dysfunction.

Keywords: sleeve gastrectomy magnesium sulfate postoperative pain bariatric surgery
study of anlotinib in patients with gastric cancer(alter0503)

Conditions: Gastric Cancer

Summary: the purpose of this study is to compare the effects and safety of anlotinib with placebo in patients with gastric cancer.


Eligibility criteria:
inclusion criteria: 1. signed and dated informed consent; 2. pathologically confirmed advanced gastric adenocarcinoma (including gastroesophageal junction adenocarcinoma) with measurable lesions outside stomach (recist 1.1) 3. advanced stomach cancer patients who have failed to the second line or higher line chemotherapy treatment 4. \>=18 years old；ecog ps：0\~1；estimated life expectancy \>3 months 5. main organs function is normal; exclusion criteria: 1. patients who have been treated with anlotinib previously; 2. patients who have been treated with other vegfr-tki small-molecule drugs previously, such as sunitinib, sorafenib, famitinib, apatinib, regorafenib, ect 3. patients suffering from other malignancies currently or within 5 years, except for cured cervical carcinoma in situ, non-melanoma skin cancers and superficial bladder cancer \[ ta (non-invasive carcinoma), tis (carcinoma in situ) and t1 (carcinoma invasion into lamina propria) \] 4. systemic anti-cancer therapy scheduled 4 weeks prior to assignment or during this study，including cytotoxic therapy，signal transduction inhibitors，immunotherapy(or received mitomycin c within 6 weeks before this study). extended field radiotherapy(ef-rt) used within 4 weeks prior to assignment or limited field radiotherapy used to assess tumor lesions within 2 weeks prior to assignment; 5. ctcae(4.0) grade 1 or higher non-remission toxicity induced by any other previous treatments，excluding alopecia and grade 2 or lower neurotoxicity induced by oxaliplatin; 6. patients with a clear tendency of gastrointestinal bleeding; 7. patients with factors that could affect oral medication (such as dysphagia，chronic diarrhea etc.) 8. patients with pleural effusion or ascites, causing respiratory syndrome (ctcae grade 2 or higher dyspnea \[grade 2 dyspnea refers to shortness of breath with a small amount of activities, affecting instrumental activities of daily life\]) 9. patients with any severe and/or unable to control diseases; 10. patients underwent major surgical treatment，open biopsy or significant traumatic injury within 28 days prior to assignment; 11. patients with any physical signs of bleeding diathesis or medical history, no matter how serious degree they are; patients with any ctcae grade 3 or higher bleeding events occurred within 4 weeks prior to assignment; patients with non-healing wounds，ulcers or fractures; 12. patients with arterial or venous thromboembolic events occurred within 6 months, such as cerebrovascular accident (including transient ischemic attack), deep vein thrombosis and pulmonary embolism; 13. patients with drug abuse history and unable to get rid of or patients with mental disorders 14. brain metastases patients with symptoms or symptoms controlled \< 2 months; 15. patients participated in other anticancer drug clinical trials within 4 weeks or patients participating in other clinical trials now;
observation in patients with diffuse large b-cell non-hodgkin's lymphoma treated on clinical trial can-ncic-ly9

Conditions: Long-term Effects Secondary to Cancer Therapy in Adults; Lymphoma

Summary: rationale: treatment for diffuse large b-cell non-hodgkin's lymphoma may cause side effects and secondary cancers later in life. an observational study that evaluates patients after undergoing six courses of combination chemotherapy with or without rituximab and radiation therapy may help doctors predict a patient's response to this treatment and help plan the best treatment. purpose: this observational study is evaluating patients with diffuse large b-cell non-hodgkin's lymphoma to see how well treatment on clinical trial can-ncic-ly9 works.

objectives: * gain information on the long-term efficacy of 6 courses of chop (cyclophosphamide, doxorubicin hydrochloride, prednisone, and vincristine)-like chemotherapy with vs without rituximab (plus involved-field radiotherapy to primary bulky disease) in young patients with good-prognosis diffuse large b-cell non-hodgkin's lymphoma treated on protocol can-ncic-ly9. * gain information on late toxicities, including secondary neoplasm occurring in young good-prognosis patients treated on protocol can-ncic-ly9. outline: this is a multicenter study. patients successfully completing treatment on protocol can-ncic-ly9 are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter. projected accrual: a total of 667 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * patients recruited for protocol can-ncic-ly9 and evaluated in the first planned final analysis as of june 2005 patient characteristics: * not specified prior concurrent therapy: * see disease characteristics

Keywords: long-term effects secondary to cancer therapy in adults stage i adult diffuse large cell lymphoma contiguous stage ii adult diffuse large cell lymphoma noncontiguous stage ii adult diffuse large cell lymphoma stage iii adult diffuse large cell lymphoma stage iv adult diffuse large cell lymphoma
impact of covid-19 on rhinovirus epidemic

Conditions: Rhinovirus

Summary: rhinovirus (rv) has long been known as the main etiological agent of "common colds" among children and adults. indeed, rv is involved in more than 50% of upper respiratory tract infections (urtis), mostly characterized by nasal congestion, rhinorrhea, sore throat and cough. rv can also cause mild to severe lower respiratory tract infections (lrtis) such as acute bronchiolitis, pneumonia and exacerbations of underlying chronic lung diseases. rv circulates worldwide, especially in temperate climate zones (i.e. many areas of the usa and europe) and is responsible for annual outbreaks from early fall to the end of spring. the covid-19 pandemic in 2020 seemed to interfere with the usual seasonal epidemics. for example, the winter respiratory syncytial virus (rsv) epidemic in lyon, france, was delayed for several months and reduced by half in terms of incidence of hospitalization cases. this can be explained by the widespread deployment of barrier gestures and social distancing measures, known as "non pharmacological interventions" (npi). however, the covid-19 pandemic doesn't seem to have the same reducing impact on rhinovirus epidemic. a better understanding of viral interactions and factors influencing rv epidemiology as well as the identification of populations at greater risk are required to improve preventive strategies and reduce the burden of rhinovirus.


Eligibility criteria:
inclusion criteria: * - child hospitalized at the " hopital femme mere enfant ", lyon, france * positive rhinovirus-pcr exclusion criteria: * - parent's refusal to participate

Keywords: rhinovirus epidemic sars-cov2/rhinovirus interaction children non-pharmacological-interventions bronchiolitis asthma pneumonia fever meningitis rhinovirus infection in children less than 1 years of age
aerosol delivery in different types of nebulizers

Conditions: Asthma

Summary: background: nebulizers design influences efficiency of aerosol delivery. performance of nebulizers is commonly tested by breathing simulators with static parameters. however, breathing patterns vary in adults. objectives: the purpose of this study was to evaluate drug deposition of different types of nebulizers testing with breathing patterns of healthy subjects.

material and methods the study was approved by chang gung memorial foundation institutional review broad. ten healthy subjects, aged 20.6±0.5 years, were recruited. four nebulizers: 1. a constant jet nebulizer (neb-easy, galemed corp., taiwan); 2. a breath enhanced nebulizer (pari lc plus, pari inc., germany); 3. a manual-actuated nebulizer (a-t neb, atlantean corporation, taiwan); and 4. a breath-actuated nebulizer (aeroelipes, trudell medical inc, canada) were evaluated.

Eligibility criteria:
inclusion criteria: * healthy college subjects exclusion criteria: * currently smoker * history of asthma * drug allergy * pulmonary disease * heart disease * arrythmia * hyperthyroids * diabetes mellitus * lactacidosis * pregnant * under b-blocker medications
ripretinib in chinese patients with advanced gist: a real world study

Conditions: Gastrointestinal Stromal Tumors

Summary: to evaluate the clinical efficacy, safety and predictive factors of ripetinib in chinese patients with advanced gist in the real world

ripretinib has become the standard ≥ 4l treatment in advanced gist. given the small sample size of patients in the china bridging study of invictus as well as the short marketing time of ripretinib, further exploration on the long-term efficacy and safety of ripretinib, as well as the dominant gene mutation type of ripretinib in chinese gist patients is required. hence, we plan to further explore the efficacy of ripretinib, predictors of efficacy, etc. by collecting and analyzing real-world data from chinese patients with advanced gist recieving ripretinib.

Eligibility criteria:
inclusion criteria: -≥18 years old * histologically confirmed gastrointestinal stromal tumor (gist) * at least one measurable lesion (mrecist v1.1) * received or receiving ripretinib treatment exclusion criteria: * patients who received \<1 cycle of ripretinib treatment * medical records are incomplete
total-body parametric 18f-fdg pet of covid-19

Conditions: Covid19

Summary: the primary objective is to measure the change between covid-19 patients and normal subjects; the secondary objective is to measure the change in covid-19 patients between baseline and 4-month follow up.


Eligibility criteria:
inclusion criteria: * covid-19 positive patients will have a previous positive covid-19 test and radiographic findings, and/or a positive sars-cov-2 antibody test and be in early recovery. * first pet/ct visit needs to be within 8 weeks of covid-19 diagnosis. * ability to understand and willingness to sign an informed consent form. * ability to adhere to the study visit schedule and other protocol requirements. * all persons ≥18 years of age. exclusion criteria: * pregnant or lactating women. * any condition that would prohibit the understanding or rendering of informed consent. * unable to lie supine for 1-hour imaging with pet. * prisoners. * any comorbidity that, in the opinion of the investigator, could compromise protocol objectives.